Market Place
Sourcing Support
Cellectis Draws €5M from European Investment Bank Credit Facility
10 Dec 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Dec 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
06 Nov 2024 //
GLOBENEWSWIRE
Cellectis Presents CAR T-cell Strategies for Solid Tumors
05 Nov 2024 //
GLOBENEWSWIRE
Cellectis drops one of its 3 clinical-stage CAR-Ts
05 Nov 2024 //
FIERCE BIOTECH
Cellectis Reports Q3 2024 Business Updates and Results
04 Nov 2024 //
GLOBENEWSWIRE
Cellectis to Report Q3 2024 Financial Results on November 4, 2024
30 Oct 2024 //
GLOBENEWSWIRE
Cellectis Presents Data On TALE-Base Editors At ESGCT
22 Oct 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
02 Oct 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Sep 2024 //
GLOBENEWSWIRE
Cellectis` MUC1 CAR T-cells Show Triple-Negative Breast Cancer Efficacy
03 Sep 2024 //
GLOBENEWSWIRE
Cellectis Publishes Article on SMART DUAL CAR T-cell Approach for Solid Tumors
26 Aug 2024 //
GLOBENEWSWIRE
Cellectis Publishes On SMART DUAL CAR T-Cell Approach For Solid Tumors
26 Aug 2024 //
GLOBENEWSWIRE
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
07 Aug 2024 //
GLOBENEWSWIRE
Cellectis Provides Financial Results for the Second Quarter 2024
06 Aug 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
05 Aug 2024 //
GLOBENEWSWIRE
FDA Grants Orphan Drug Designation To Cellectis` CLLS52 For ALL
01 Aug 2024 //
GLOBENEWSWIRE
FDA Grants Orphan And Rare Pediatric Status To Cellectis` UCART22 For ALL
25 Jul 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
05 Jul 2024 //
GLOBENEWSWIRE
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
28 Jun 2024 //
GLOBENEWSWIRE
Cellectis Article Reveals Three Key Factors For Efficient TALE Base Editing
20 Jun 2024 //
GLOBENEWSWIRE
Cellectis Unveils Non-Viral Gene Therapy For Sickle Cell Disease
12 Jun 2024 //
GLOBENEWSWIRE
Cellectis gets European orphan drug designation for its candidate UCART22
06 Jun 2024 //
PHARMABIZ
Monthly information on share capital and company voting rights
05 Jun 2024 //
GLOBENEWSWIRE
Cellectis: Orphan Status For UCART22 In Acute Lymphoblastic Leukemia
04 Jun 2024 //
GLOBENEWSWIRE
Cellectis™ Annual Shareholders General Meeting to be Held on June 28, 2024
29 May 2024 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for First Quarter 2024
28 May 2024 //
GLOBENEWSWIRE
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
27 May 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
16 May 2024 //
GLOBENEWSWIRE
AstraZeneca completes equity investment agreement with Cellectis
08 May 2024 //
INDINPHARMAPOST
AstraZeneca completes equity investment agreement with Cellectis
07 May 2024 //
PRESS RELEASE
Cellectis: AstraZeneca Completes Additional Equity Investment
06 May 2024 //
GLOBENEWSWIRE
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
02 May 2024 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
29 Apr 2024 //
GLOBENEWSWIRE
Cellectis Novel TALEN Gene Editing Processes At ASGCT
22 Apr 2024 //
GLOBENEWSWIRE
Cellectis Publishes Novel Intronic Gene Editing Approach
10 Apr 2024 //
GLOBENEWSWIRE
Cellectis Announces Poster Presentations at the ASGCT Annual Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Monthly Information on Share Capital and Company Voting Rights
04 Apr 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Mar 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
02 Feb 2024 //
GLOBENEWSWIRE
Cellectis announces the drawdown of the second tranche of ‚¬15 million
16 Jan 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
08 Jan 2024 //
GLOBENEWSWIRE
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
22 Dec 2023 //
GLOBENEWSWIRE
Cellectis shifts CAR-T manufacturing in-house
07 Dec 2023 //
ENDPTS
Monthly information on share capital and company voting rights
01 Dec 2023 //
GLOBENEWSWIRE
Cellectis™ Shareholders Meeting to be Held on December 22, 2023
17 Nov 2023 //
GLOBENEWSWIRE
Cellectis Announces the execution of the Subsequent Investment Agreement with AZ
15 Nov 2023 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
06 Nov 2023 //
GLOBENEWSWIRE
BeiGene touts Brukinsa data, Cellectis compares CAR-T to CDMO CAR-T
03 Nov 2023 //
ENDPTS
Monthly information on share capital and company voting rights
03 Nov 2023 //
GLOBENEWSWIRE
Cellectis to Present Results of NATHALI_01 and BALLI_01 Phases I Trials
02 Nov 2023 //
GLOBENEWSWIRE
AstraZeneca to invest $245 mln in Cellectis to boost gene therapy prospects
02 Nov 2023 //
REUTERS
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
01 Nov 2023 //
GLOBENEWSWIRE
Cellectis Presents Data on Multi-armored Allogeneic MUC1-CAR T-cells
31 Oct 2023 //
GLOBENEWSWIRE
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program
24 Oct 2023 //
GLOBENEWSWIRE
Cellectis and Imagine Institute Publish A Study of a Gene Surgery Candidate
12 Oct 2023 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
03 Oct 2023 //
GLOBENEWSWIRE
Cellectis to Present Data on Multi-armored Allogeneic MUC1-CAR T-cells
27 Sep 2023 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
05 Sep 2023 //
GLOBENEWSWIRE
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
